5-chloro-4'-methylsalicylanilide | 4638-50-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-chloro-4'-methylsalicylanilide
• 英文别名: 5-chloro-2-hydroxy-benzoic acid p-toluidide；5-Chlor-2-hydroxy-benzoesaeure-p-toluidid；5-Chlorsalicyl-p-toluidid；Benzamide, 5-chloro-2-hydroxy-N-(4-methylphenyl)-；5-chloro-2-hydroxy-N-(4-methylphenyl)benzamide
• CAS: 4638-50-0
• 化学式: C₁₄H₁₂ClNO₂
• 分子量: 261.708
• InChiKey: KLORATCDRSXVPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-chloro-4'-methylsalicylanilide 在 盐酸 、 溶剂黄146 、 N,N'-二环己基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.5h， 生成
  参考文献：
  名称：

  New derivatives of salicylamides: Preparation and antimicrobial activity against various bacterial species

  摘要：

  Three series of salicylanilides, esters of N-phenylsalicylamides and 2-hydroxy-N-[1-(2-hydroxyphenylamino)-1-oxoalkan-2-yl]benzamides, in total thirty target compounds were synthesized and characterized. The compounds were evaluated against seven bacterial and three mycobacterial strains. The antimicrobial activities of some compounds were comparable or higher than the standards ampicillin, ciprofloxacin or isoniazid. Derivatives 3f demonstrated high biological activity against Staphylococcus aureus (<= 0.03 mu mol/L), Mycobacterium marinum (<= 0.40 mu mol/L) and Mycobacterium kansasii (1.58 mu mol/L), 3g shows activity against Clostridium perfringens (<= 0.03 mu mol/L) and Bacillus cereus (0.09 mu mol/L), 3h against Pasteurella multocida (<= 0.03 mu mol/L) and M. kansasii (<= 0.43 mu mol/L), 3i against methicillin-resistant S. aureus and B. cereus (<= 0.03 mu mol/L). The structure-activity relationships are discussed for all the compounds. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.08.029
• 作为产物：
  描述：

  2-羟基-N-(对甲苯基)苯甲酰胺 在 磺酰氯 、 苯 作用下， 生成 5-chloro-4'-methylsalicylanilide
  参考文献：
  名称：

  Hirwe; Jadhav; Sukhtankar, Journal of the Indian Chemical Society, 1939, vol. 16, p. 281,284

  摘要：

  DOI：

文献信息

• Double 1,4-addition of (thio)salicylamides/thiosalicylic acids with propiolate derivatives: a direct, general synthesis of diverse heterocyclic scaffolds
  作者：Hui-Hong Wang、Tao Shi、Wei-Wei Gao、Hong-Hua Zhang、Yong-Qiang Wang、Jun-Fang Li、Yong-Sheng Hou、Jin-Hong Chen、Xue Peng、Zhen Wang

  DOI：10.1039/c7ob02101a

  日期：——

  ring-closure procedure to prepare a range of diverse heterocycles has been developed. In this transformation, a variety of substituted (thio)salicylamides and thiosalicylic acids occured double 1, 4-additions reaction with propiolate derivatives in the presence of inorganic base (K3PO4), as a result, benzothiazinones, benzoxazinones and benzoxathiinones were prepared in good to excellent yields respectively

  已经开发了一种简单实用的闭环方法来制备一系列不同的杂环。在该转化过程中，在无机碱（K3PO4）存在下，各种取代的（硫代）水杨酰胺和硫代水杨酸与丙酸酯衍生物发生了双1、4加成反应，结果制备了苯并噻嗪酮，苯并恶嗪酮和苯并噻吩并酮即使以克为单位，也具有出色的产量。另外，还成功地进行了向更复杂结构和奥昔康药物类似物的进一步转化。
• Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection
  作者：Khalida Shamim、Miao Xu、Xin Hu、Emily M Lee、Xiao Lu、Ruili Huang、Pranav Shah、Xin Xu、Catherine Z. Chen、Min Shen、Hui Guo、Lu Chen、Zina Itkin、Richard T. Eastman、Paul Shinn、Carleen Klumpp-Thomas、Sam Michael、Anton Simeonov、Donald C. Lo、Guo-li Ming、Hongjun Song、Hengli Tang、Wei Zheng、Wenwei Huang

  DOI：10.1016/j.bmcl.2021.127906

  日期：2021.5

  focusing on the anilide and salicylic acid regions of niclosamide to improve physicochemical properties such as microsomal metabolic stability, permeability and solubility. We found that the 5-bromo substitution in the salicylic acid region retains potency while providing better drug-like properties. Other modifications in the anilide region with 2′-OMe and 2′-H substitutions were also advantageous

  寨卡病毒已成为全球人类健康的潜在威胁。之前的药物再利用筛选确定已批准的驱虫药氯硝柳胺是寨卡病毒感染的小分子抑制剂。然而，由于抗蠕虫药物通常设计为口服时吸收率较低，氯硝柳胺非常有限的生物利用度可能会阻碍其直接重新用作抗病毒药物。在这里，我们针对氯硝柳胺的苯胺和水杨酸区域进行了 SAR 研究，以改善微粒体代谢稳定性、渗透性和溶解性等理化性质。我们发现水杨酸区域的 5-溴取代保留了效力，同时提供了更好的药物样特性。具有 2'-OMe 和 2'-H 取代的苯胺区域的其他修饰也是有利的。我们发现4'-NO 2取代基可以被4'-CN或4'-CF 3取代基取代。总之，这些修饰为优化氯硝柳胺的结构提供了基础，以改善氯硝柳胺类似物作为治疗寨卡和其他病毒感染的药物先导候选药物的全身暴露。事实上，关键的类似物也能够将细胞从 SARS-CoV-2 感染的细胞病变效应中拯救出来，这表明与针对 COVID-19 大流行的治疗策略的相关性。
• [EN] SMALL MOLECULE INHIBITORS OF SARS-COV-2 INFECTIONS<br/>[FR] INHIBITEURS À PETITES MOLÉCULES D'INFECTIONS PAR SARS-COV-2
  申请人：THE USA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES

  公开号：WO2022109148A1

  公开（公告）日：2022-05-27

  The present disclosure relates generally to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), commonly referred to as coronavirus disease 2019 (COVID-19). The present disclosure relates more particularly to small molecule inhibitors of SARS-CoV-2 of Formula (II) and prodrug derivatives thereof of Formula (I), and methods of treating COVID-19 therewith.

  本公开涉及化合物、包含它们的药物组合物以及使用这些化合物和组合物治疗由严重急性呼吸综合症冠状病毒2（SARS-CoV-2）引起的疾病，通常称为2019冠状病毒病（COVID-19）的方法。本公开特别涉及SARS-CoV-2的小分子抑制剂II式和其前药衍生物I式，以及使用它们治疗COVID-19的方法。
• Halogenated salicylanilides for treating clostridium infections
  申请人：UNION therapeutics A/S

  公开号：US10463680B2

  公开（公告）日：2019-11-05

  The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhea and C. difficile associated colitis.

  本发明涉及卤代水杨酰苯胺或其药学上可接受的盐或酯，用于治疗梭状芽孢杆菌引起的受试者感染，特别是艰难梭菌感染。卤代水杨酰苯胺有望用于治疗艰难梭菌相关疾病，包括艰难梭菌相关腹泻和艰难梭菌相关结肠炎。
• Halogenated salicylanilides for treating Clostridium infections
  申请人：UNION therapeutics A/S

  公开号：US10857164B2

  公开（公告）日：2020-12-08

  The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhoea and C. difficile associated colitis.

  本发明涉及卤代水杨酰苯胺或其药学上可接受的盐或酯，用于治疗梭状芽孢杆菌引起的受试者感染，特别是艰难梭菌感染。卤代水杨酰苯胺有望用于治疗艰难梭菌相关疾病，包括艰难梭菌相关腹泻和艰难梭菌相关结肠炎。